Gerardo Abel FernĆ”ndez š¦š·, born on October 29, 1976, in BahĆa Blanca, Argentina, is a researcher specializing in neuroscience and cognitive science š§ . He is a professor and adjunct researcher at CONICET, focusing on eye movement-based biomarkers for neurodegenerative diseases š. His work integrates philosophy, cognitive psychology, and technology to advance Alzheimerās diagnosis š„.
Profile
Education š
š Gerardo Abel FernĆ”ndez obtained a degree in Philosophy (2003) from Universidad Nacional del Sur (UNS), Argentina, with a specialization in Logic and Epistemology. He later pursued a PhD in Philosophy (2011) at UNS, with his thesis titled “Dynamic word processing during reading: Mental strategies driving visual exploration”, earning a perfect 10/10 with special mention. His academic journey includes postdoctoral research as a fellow at AGENCIA (ANPCYT) and the DAAD Max Planck Institute in Berlin. His educational background bridges philosophy, neuroscience, and cognitive psychology, forming a solid foundation for his pioneering research in eye movement analysis and Alzheimerās biomarkers. His expertise in cognitive science and technological innovation has led to the development of diagnostic tools for early neurodegenerative disease detection. ššš§
Experience šØāš«
š¼ Dr. Gerardo Abel FernĆ”ndez has extensive experience in neuroscience research and technological innovation. He served as a Professor of Audiovisual Language at UNS (2011ā2013) and is currently an Adjunct Researcher at CONICET, focusing on non-endemic degenerative pathologies. He has worked as a Visiting Scholar at Heriot-Watt University and Strathclyde University (UK), contributing to the development of eye-tracking biomarkers for Alzheimerās disease. Dr. FernĆ”ndez is also a scientific reviewer for prestigious journals like PlosOne, Journal of Alzheimerās Disease, and Neuropsychologia. As CTO of Viewmind, he leads biocognitive and functional performance measurement innovations. He has patented cognitive evaluation methods and received grants from institutions like ANPCYT and DAAD. His interdisciplinary expertise spans cognitive neuroscience, machine learning applications in diagnostics, and technological development for neurodegenerative disease assessment. š
š¬šļø
Research Interests š¬
š¬ Dr. Gerardo Abel FernĆ”ndez specializes in cognitive neuroscience, neurodegenerative disease biomarkers, and eye-tracking technology. His research focuses on early Alzheimerās detection through oculomotor behavior analysis. He has developed innovative methods to study visual exploration, reading difficulties, and memory impairments in neurodegenerative conditions. His work integrates machine learning and artificial intelligence for cognitive assessment tools. As a Visiting Scholar in the UK, he contributed to developing biomarkers for Alzheimerās disease. His patented eye-tracking system has clinical applications in detecting mild cognitive impairment and Alzheimerās disease. He has published extensively in peer-reviewed journals, exploring predictive eye movement models and their correlation with cognitive decline. His cutting-edge research bridges philosophy, neuroscience, and technology, offering non-invasive diagnostic solutions for early-stage neurodegeneration. His ultimate goal is to revolutionize cognitive healthcare through technological innovation. š§ šļøš
Awards & Recognitions š
š Dr. Gerardo Abel FernĆ”ndez has received numerous awards for his contributions to neuroscience, cognitive evaluation, and Alzheimerās diagnostics. His eye-tracking research for Alzheimerās detection earned the Dr. JosĆ© Borda Clinical Psychiatry Prize at the 22nd International Congress of Psychiatry. He won the Novartis Innovation Award for his work on measuring cognitive performance in health and disease. As CTO of Viewmind, his team received international recognition, including the Fit4Start Luxembourg Award for health applications and the Medica Innovation Prize in DĆ¼sseldorf. His research and patented cognitive evaluation equipment have been acknowledged by ANMAT (Argentinaās National Administration of Drugs, Foods, and Medical Technology) and INPI (Argentinaās National Patent Office). Dr. FernĆ”ndez’s groundbreaking innovations in neurocognitive assessments have positioned him as a leading figure in technological advancements for early Alzheimerās detection. š
š§ š¬
Publications š
-
Oculomotor behaviors and integrative memory functions in the alzheimer’s clinical syndrome
Journal of Alzheimer’s Disease
2021 |Ā Journal article
-
A non-invasive tool for attention-deficit disorder analysis based on gaze tracks.
ACM International Conference Proceeding Series
2019 |Ā Conference paper
-
Microsaccadic behavior when developing a complex dynamical activity
Journal of Integrative Neuroscience
2018 |Ā Journal article